Maze Therapeutics, Inc. Common Stock (MAZE) is a publicly traded Healthcare sector company. As of May 21, 2026, MAZE trades at $25.03 with a market cap of $1.36B and a P/E ratio of -9.98. MAZE moved +2.37% today. Year to date, MAZE is -35.21%; over the trailing twelve months it is +147.58%. Its 52-week range spans $6.71 to $53.65. Analyst consensus is strong buy with an average price target of $63.50. Rallies surfaces MAZE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies organizes MAZE SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
| Metric | Value |
|---|---|
| Price | $25.03 |
| Market Cap | $1.36B |
| P/E Ratio | -9.98 |
| EPS | $-2.48 |
| Dividend Yield | 0.00% |
| 52-Week High | $53.65 |
| 52-Week Low | $6.71 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $20.00M |
| Net Income | $-122.54M |
| Gross Margin | 0.00% |
12 analysts cover MAZE: 0 strong buy, 12 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $63.50.